Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 464

1.

ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries.

Jones RN, Kohno S, Ono Y, Ross JE, Yanagihara K.

Diagn Microbiol Infect Dis. 2009 Jun;64(2):191-201. doi: 10.1016/j.diagmicrobio.2009.03.001.

PMID:
19500528
2.

Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.

Jones RN, Ross JE, Bell JM, Utsuki U, Fumiaki I, Kobayashi I, Turnidge JD.

Diagn Microbiol Infect Dis. 2009 Dec;65(4):404-13. doi: 10.1016/j.diagmicrobio.2009.10.001.

PMID:
19913683
3.

Linezolid surveillance program results for 2008 (LEADER Program for 2008).

Farrell DJ, Mendes RE, Ross JE, Jones RN.

Diagn Microbiol Infect Dis. 2009 Dec;65(4):392-403. doi: 10.1016/j.diagmicrobio.2009.10.011.

PMID:
19913682
4.

Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.

Anderegg TR, Sader HS, Fritsche TR, Ross JE, Jones RN.

Int J Antimicrob Agents. 2005 Jul;26(1):13-21.

PMID:
15967640
5.
6.

Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.

Jones RN, Ross JE, Fritsche TR, Sader HS.

J Antimicrob Chemother. 2006 Feb;57(2):279-87. Epub 2005 Dec 2.

PMID:
16326811
7.

Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.

Ross JE, Anderegg TR, Sader HS, Fritsche TR, Jones RN.

Diagn Microbiol Infect Dis. 2005 May;52(1):53-8.

PMID:
15878443
8.

Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.

Ross JE, Fritsche TR, Sader HS, Jones RN.

Int J Antimicrob Agents. 2007 Mar;29(3):295-301. Epub 2007 Jan 18.

PMID:
17239570
9.

Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000.

Mutnick AH, Biedenbach DJ, Turnidge JD, Jones RN.

Diagn Microbiol Infect Dis. 2002 May;43(1):65-73.

PMID:
12052631
10.
11.

A multicenter evaluation of linezolid antimicrobial activity in North America.

Ballow CH, Jones RN, Biedenbach DJ; North American ZAPS Research Group.

Diagn Microbiol Infect Dis. 2002 May;43(1):75-83.

PMID:
12052632
12.

LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).

Jones RN, Fritsche TR, Sader HS, Ross JE.

Diagn Microbiol Infect Dis. 2007 Nov;59(3):309-17. Epub 2007 Aug 27.

PMID:
17720350
13.

Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific.

Bell JM, Turnidge JD, Ballow CH, Jones RN; ZAPS Regional Participants.

J Antimicrob Chemother. 2003 Feb;51(2):339-45.

PMID:
12562700
14.

ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries.

Flamm RK, Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN.

J Chemother. 2012 Dec;24(6):328-37. doi: 10.1179/1973947812Y.0000000039.

PMID:
23174097
16.

An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011.

Flamm RK, Mendes RE, Ross JE, Sader HS, Jones RN.

Diagn Microbiol Infect Dis. 2013 Jun;76(2):206-13. doi: 10.1016/j.diagmicrobio.2013.01.025. Epub 2013 Mar 9.

PMID:
23478031
17.

United States resistance surveillance results for linezolid (LEADER Program for 2007).

Jones RN, Ross JE, Castanheira M, Mendes RE.

Diagn Microbiol Infect Dis. 2008 Dec;62(4):416-26. doi: 10.1016/j.diagmicrobio.2008.10.010.

PMID:
19022153
18.

TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens.

Jones RN, Moet GJ, Sader HS, Mendes RE, Castanheira M.

J Antimicrob Chemother. 2009 Apr;63(4):716-20. doi: 10.1093/jac/dkp021. Epub 2009 Feb 13.

PMID:
19218276
19.

In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.

Cercenado E, GarcĂ­a-Garrote F, Bouza E.

J Antimicrob Chemother. 2001 Jan;47(1):77-81.

PMID:
11152434
20.

Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe).

Bolmstrom A, Ballow CH, Qwarnstrom A, Biedenbach DJ, Jones RN.

Clin Microbiol Infect. 2002 Dec;8(12):791-800.

Supplemental Content

Support Center